<iframe src="https://www.googletagmanager.com/ns.html?id=GTM-TNV5PS3" height="0" width="0" style="display:none;visibility:hidden">

Company Showcase

Karius_Pickup-logo_Final-01-1 Study: Pneumonia in the ImmunoCompromised - Use of the Karius Test® for the Detection of Undiagnosed Pathogens

Pneumonia is a common infectious cause of morbidity and mortality in patients with hematologic malignancies and those post hematopoietic cell transplantation (HCT). The PICKUP study, a multi-center, prospective study, interrogates this population for the etiology of pneumonia by comparing the performance of the Karius Test to the adjudicated Standard of Care (SOC). During this presentation, results will be shared on the additive diagnostic value of the Karius Test when used in conjunction with SOC for the diagnosis of suspected pneumonia.

David Berman, DO

Medical Director - Karius

*Not an official event of the 64th ASH Annual Meeting and Exposition. This presentation is not sponsored or endorsed by ASH. Not CME-accredited.

Abstracts & Posters

Poster #2040
Plasma Microbial Cell-Free DNA to Characterize Infection vs Cytokine Release Syndrome in Pediatric Patients with B ALL after CAR T Cell Therapy

Presenting Author: Catherine Aftandilian, MD - Stanford Medicine Children's Health

Saturday, December 10 I 5:30 - 7:30 pm CT I Hall D

Stay up-to-date with Karius

Sign up today to receive notification of future real-world cases of the Karius Test being used by physicians and upcoming events.


What is the Karius Test?

The Karius Test is a non-invasive liquid biopsy needing only a single blood sample to rapidly detect over 1,000 pathogens causing both deep-seated and bloodstream infections.
1 blood sample
Vector Smart Object (1)
1-day processing
Vector Smart Object (2)
1000+ pathogens

*The Karius Test® was developed and its performance characteristics determined by Karius. This test has not been cleared or approved by the FDA, nor is it required to be. The Karius laboratory is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA ’88) and is accredited by the College of American Pathologists (CAP) to perform high-complexity clinical laboratory testing.